Prescription Required 
Formulation : 
Description
Indications
The umeclidinium and vilanterol combination is used for the management of symptoms such as wheezing, coughing, shortness of breath, and chest tightness, which are commonly associated with chronic obstructive pulmonary disease (COPD). COPD encompasses a range of lung and airway disorders, including chronic bronchitis and emphysema.
Umeclidinium belongs to the anticholinergic class of drugs, while vilanterol is classified as a long-acting beta-agonist (LABA). These agents exert their therapeutic effects by inducing relaxation and dilation of the air passages within the lungs, thus promoting ease of breathing.
The use of umeclidinium and vilanterol is not approved for the treatment of asthma. Individuals with asthma who use long-acting inhaled beta agonists, such as vilanterol, without also using an inhaled corticosteroid may be at an increased risk of experiencing serious breathing problems, which may be fatal.
Uses and Dosage
The combination of umeclidinium and vilanterol is available as an orally inhaled powder through a specialized inhaler, and is typically administered once daily. Consistently inhale this medication at the same time each day, following the instructions on the prescription label. Use umeclidinium and vilanterol precisely as directed by a doctor, and to refrain from using more or less of it, or using it more frequently than prescribed.
It is not recommended to use umeclidinium and vilanterol inhalation for sudden attacks of COPD, as a short-acting beta agonist medication, such as albuterol, is typically prescribed for this purpose. If a patient was previously using this type of medication on a regular basis, their doctor may advise them to cease using it regularly but continue to use it during attacks.
Patients should not utilize umeclidinium and vilanterol inhalation to treat rapidly deteriorating COPD. If breathing difficulties become more severe, short-acting inhalers must be used more frequently, or symptoms are not relieved by a short-acting inhaler, individuals should immediately contact their physician or seek emergency medical assistance.
Although umeclidinium and vilanterol inhalation can manage COPD, it is not curative. Patients should continue to use this medication even if they feel well, and should not halt usage without consulting with a physician, as ceasing use may exacerbate symptoms.
Before administering umeclidinium and vilanterol inhalation for the first time, seek guidance from a physician, pharmacist, or respiratory therapist to ensure proper usage. Practicing inhaler usage with a healthcare professional present is advised.
Side Effects
Some side effects may occur that usually do not need medical attention:
- diarrhea
- difficulty having a bowel movement
- muscle spasms
Inform your healthcare provider immediately if you experience any serious side effects:
- body aches or pain
- chest pain
- congestion
- cough
- dryness or soreness of the throat
- fever
- headache
- hoarseness
- pain or tenderness around the eyes and cheekbones
- stuffy or runny nose
- tender, swollen glands in the neck
- tightness of the chest
- trouble breathing
- trouble swallowing
- voice changes
Caution
Prior to using umeclidinium/vilanterol, inform your physician or pharmacist of any allergies you may have to either drug or any other substances. Inactive ingredients contained in this product, such as milk proteins, have the potential to cause allergic reactions or other complications.
Before use of this medication, discuss your medical history with your doctor or pharmacist, particularly if you have previously experienced heart issues, high blood pressure, seizures, overactive thyroid, diabetes, or personal or familial instances of glaucoma (angle-closure type), or difficulty urinating (such as due to an enlarged prostate).
Umeclidinium/vilanterol may result in QT prolongation, which is a condition that can affect the heart rhythm. In rare cases, QT prolongation can cause fast or irregular heartbeat, along with other symptoms (such as severe dizziness or fainting) that necessitate immediate medical attention. If you have low levels of potassium or magnesium in your blood, your risk of QT prolongation may be increased. This risk may also be elevated if you are using certain medications (such as diuretics or “water pills”) or if you are experiencing severe sweating, diarrhea, or vomiting.
Older adults may be more susceptible to the side effects associated with this medication, particularly QT prolongation.
If you are pregnant, this medication should only be used when absolutely necessary, and you should discuss the potential risks and benefits with your doctor.
It is unclear if this medication is present in breast milk. Please consult with your doctor before nursing.
Form and Strength
Anoro Ellipta is available in the following forms and strengths:
-
Anoro Ellipta dry powder inhaler:
- 62.5/25mcg
FAQ
Is Anoro Ellipta a steroid inhaler?
No, Anoro Ellipta is not a steroid. It’s a long-acting muscarinic antagonist (LAMA) and a long-acting beta-agonist (LABA).
Do you need to rinse your mouth after Anoro Ellipta?
Rinse your mouth thoroughly with water after taking this medication to reduce your risk of developing a sore mouth or throat.
Resources
- https://www.goodrx.com/anoro-ellipta/what-is
- https://www.med.umich.edu/1libr/COPD/Inhalers/AnoroEllipta.pdf
- https://www.mayoclinic.org/drugs-supplements/umeclidinium-and-vilanterol-inhalation-route/side-effects/drg-20088458?p=1
- https://medlineplus.gov/druginfo/meds/a614019.html
- https://reference.medscape.com/drug/anoro-ellipta-umeclidinium-bromide-vilanterol-inhaled-999892
- https://www.webmd.com/drugs/2/drug-165814/anoro-ellipta-inhalation/details
- https://www.drugs.com/anoro-ellipta.html
